Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 623759, 12 pages
http://dx.doi.org/10.1155/2014/623759
Review Article

The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis

1Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
2Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea & Westminster Hospital, London SW10 9NH, UK

Received 6 February 2014; Accepted 25 June 2014; Published 7 July 2014

Academic Editor: Chung-Hsi Hsing

Copyright © 2014 Bob Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. K. Kolls and A. Linden, “Interleukin-17 family members and inflammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004. View at Google Scholar
  4. L. Yang, D. E. Anderson, C. Baecher-Allan et al., “IL-21 and TGF-β are required for differentiation of human T H17 cells,” Nature, vol. 454, no. 7202, pp. 350–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Manel, D. Unutmaz, and D. R. Littman, “The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt,” Nature Immunology, vol. 9, no. 6, pp. 641–649, 2008. View at Publisher · View at Google Scholar
  6. P. Miossec, T. Korn, and V. K. Kuchroo, “Interleukin-17 and type 17 helper T cells,” The New England Journal of Medicine, vol. 361, no. 9, pp. 888–898, 2009. View at Google Scholar
  7. W. Ouyang, J. K. Kolls, and Y. Zheng, “The biological functions of T helper 17 cell effector cytokines in inflammation,” Immunity, vol. 28, no. 4, pp. 454–467, 2008. View at Publisher · View at Google Scholar
  8. P. Ye, F. H. Rodriguez, S. Kanaly et al., “Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense,” The Journal of Experimental Medicine, vol. 194, no. 4, pp. 519–527, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. N. Kelly, J. K. Kolls, K. Happel et al., “Interteukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection,” Infection and Immunity, vol. 73, no. 1, pp. 617–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Huang, L. Na, P. L. Fidel, and P. Schwarzenberger, “Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice,” Journal of Infectious Diseases, vol. 190, no. 3, pp. 624–631, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Zelante, A. de Luca, P. Bonifazi et al., “IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance,” European Journal of Immunology, vol. 37, no. 10, pp. 2695–2706, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. C. S. Ma, G. Y. Chew, N. Simpson et al., “Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3,” The Journal of Experimental Medicine, vol. 205, no. 7, pp. 1551–1557, 2008. View at Publisher · View at Google Scholar
  13. J. D. Milner, J. M. Brenchley, A. Laurence et al., “Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome,” Nature, vol. 452, no. 7188, pp. 773–776, 2008. View at Publisher · View at Google Scholar
  14. K. Sato, A. Suematsu, K. Okamoto et al., “Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction,” The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673–2682, 2006. View at Google Scholar
  15. B. W. Kirkham, M. N. Lassere, J. P. Edmonds et al., “Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort),” Arthritis and Rheumatism, vol. 54, no. 4, pp. 1122–1131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Komatsu, K. Okamoto, S. Sawa et al., “Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis,” Nature Medicine, vol. 20, no. 1, pp. 62–68, 2014. View at Publisher · View at Google Scholar
  17. K. Ray, “Experimental arthritis. Tipping the balance: conversion of Foxp3+ T cells to TH17 cells is crucial in autoimmune arthritis,” Nature Reviews Rheumatology, vol. 10, no. 2, p. 63, 2014. View at Publisher · View at Google Scholar
  18. S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Rovedatti, T. Kudo, P. Biancheri et al., “Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease,” Gut, vol. 58, no. 12, pp. 1629–1636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Sarra, F. Pallone, T. T. MacDonald, and G. Monteleone, “IL-23/IL-17 axis in IBD,” Inflammatory Bowel Diseases, vol. 16, no. 10, pp. 1808–1813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Seiderer, I. Elben, J. Diegelmann et al., “Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD,” Inflammatory Bowel Diseases, vol. 14, no. 4, pp. 437–445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Olsen, R. Rismo, G. Cui, R. Goll, I. Christiansen, and J. Florholmen, “TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation,” Cytokine, vol. 56, no. 3, pp. 633–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Zhang, M. Zheng, J. Bindas, P. Schwarzenberger, and J. K. Kolls, “Critical role of IL-17 receptor signaling in acute TNBS-induced colitis,” Inflammatory Bowel Diseases, vol. 12, no. 5, pp. 382–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Murugaiyan and B. Saha, “Protumor vs antitumor functions of IL-17,” The Journal of Immunology, vol. 183, no. 7, pp. 4169–4175, 2009. View at Google Scholar
  25. T. Iida, M. Iwahashi, M. Katsuda et al., “Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer,” Oncology Reports, vol. 25, no. 5, pp. 1271–1277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Kryczek, K. Wu, E. Zhao et al., “IL-17+ regulatory T Cells in the microenvironments of chronic inflammation and cancer,” The Journal of Immunology, vol. 186, no. 7, pp. 4388–4395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. D. He, H. Li, N. Yusuf et al., “IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells,” Journal of Immunology, vol. 184, no. 5, pp. 2281–2288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Wang, Y. Zhang, Y. Liu et al., “Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients,” Journal of Immunotherapy, vol. 37, no. 1, pp. 43–50, 1997. View at Publisher · View at Google Scholar
  29. P. Miossec, “IL-17 and Th17 cells in human inflammatory diseases,” Microbes and Infection, vol. 11, no. 5, pp. 625–630, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Miao, S. Sheng, X. Sun, J. Liu, and G. Huang, “Lactate dehydrogenase a in cancer: a promising target for diagnosis and therapy,” IUBMB Life, vol. 65, no. 11, pp. 904–910, 2013. View at Google Scholar
  31. M. Yabu, H. Shime, H. Hara et al., “IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid,” International Immunology, vol. 23, no. 1, pp. 29–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Shime, M. Yabu, T. Akazawa et al., “Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway,” The Journal of Immunology, vol. 180, no. 11, pp. 7175–7183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Wang, T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu, “IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway,” The Journal of Experimental Medicine, vol. 206, no. 7, pp. 1457–1464, 2009. View at Publisher · View at Google Scholar
  34. H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews Cancer, vol. 9, no. 11, pp. 798–809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Kumar, Y. Takada, A. M. Boriek, and B. B. Aggarwal, “Nuclear factor-κB: its role in health and disease,” Journal of Molecular Medicine, vol. 82, no. 7, pp. 434–448, 2004 (English). View at Google Scholar · View at Scopus
  36. C. K. Huang, C. Y. Yang, Y. M. Jeng et al., “Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-κB-mediated antiapoptotic pathway,” Oncogene, vol. 33, no. 23, pp. 2968–2977, 2013. View at Publisher · View at Google Scholar
  37. D. S. Straus, “TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells,” Molecular Cancer, vol. 12, article 78, 2013. View at Publisher · View at Google Scholar
  38. K. Mizutani, S. Sud, N. A. McGregor et al., “The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment,” Neoplasia, vol. 11, no. 11, pp. 1235–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. E. V. Vykhovanets, G. T. MacLennan, O. V. Vykhovanets, and S. Gupta, “IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 6, pp. 552–565, 2011. View at Google Scholar · View at Scopus
  40. S. I. Grivennikov and M. Karin, “Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer,” Cytokine & Growth Factor Reviews, vol. 21, no. 1, pp. 11–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Yu and R. Jove, “The stats of cancer—new molecular targets come of age,” Nature Reviews Cancer, vol. 4, no. 2, pp. 97–105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. J. A. Zepp, C. Liu, M. F. Gulen et al., “296: IL-17-signaling in LGR5-positive stem cells promotes colon tumorigenesis,” Cytokine, vol. 63, no. 3, p. 313, 2013. View at Google Scholar
  43. A. Saxena, S. K. Raychaudhuri, and S. P. Raychaudhuri, “Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent,” Arthritis and Rheumatism, vol. 63, no. 5, pp. 1465–1466, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Huang, H. J. Kim, E.-J. Chang et al., “IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling,” Cell Death and Differentiation, vol. 16, no. 10, pp. 1332–1343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ankathatti Munegowda, Y. Deng, S. J. Mulligan, and J. Xiang, “Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity,” Cancer Immunology, Immunotherapy, vol. 60, no. 10, pp. 1473–1484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Benchetrit, A. Ciree, V. Vives et al., “Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism,” Blood, vol. 99, no. 6, pp. 2114–2121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Kryczek, S. Wei, W. Szeliga, L. Vatan, and W. Zou, “Endogenous IL-17 contributes to reduced tumor growth and metastasis,” Blood, vol. 114, no. 2, pp. 357–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Karin, “Nuclear factor-kappaB in cancer development and progression,” Nature, vol. 441, no. 7092, pp. 431–436, 2006. View at Google Scholar
  51. J. Folkman, “Angiogenesis,” Annual Review of Medicine, vol. 57, no. 1, pp. 1–18, 2006. View at Publisher · View at Google Scholar
  52. D. F. Yao, X. H. Wu, Y. Zhu et al., “Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma,” Hepatobiliary & Pancreatic Diseases International, vol. 4, no. 2, pp. 220–226, 2005. View at Google Scholar
  53. Y. M. El-Gohary, J. F. Silverman, P. R. Olson et al., “Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma,” American Journal of Clinical Pathology, vol. 127, no. 4, pp. 572–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Iavarone, P. Lampertico, F. Iannuzzi et al., “Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma,” Journal of Viral Hepatitis, vol. 14, no. 2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Kopfstein, T. Veikkola, V. G. Djonov et al., “Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis,” The American Journal of Pathology, vol. 170, no. 4, pp. 1348–1361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Möbius, C. Demuth, T. Aigner et al., “Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma,” European Journal of Surgical Oncology, vol. 33, no. 8, pp. 1025–1029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Qi, X. Huang, and J. Wang, “Correlation between Th17 cells and tumor microenvironment,” Cellular Immunology, vol. 285, no. 1-2, pp. 18–22, 2013. View at Publisher · View at Google Scholar
  58. L. A. Pekarek, B. A. Starr, A. Y. Toledano, and H. Schreiber, “Inhibition of tumor growth by elimination of granulocytes,” The Journal of Experimental Medicine, vol. 181, no. 1, pp. 435–440, 1995. View at Google Scholar
  59. D. A. Arenberg, S. L. Kunkel, P. J. Polverini et al., “Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases,” The Journal of Experimental Medicine, vol. 184, no. 3, pp. 981–992, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. B. B. Moore, D. A. Arenberg, C. L. Addison, M. P. Keane, P. J. Polverini, and R. M. Strieter, “CXC chemokines mechanism of action in regulating tumor angiogenesis,” Angiogenesis, vol. 2, no. 2, pp. 123–134, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Kehlen, K. Thiele, D. Riemann, N. Rainov, and J. Langner, “Interleukin-17 stimulates the expression of IκBα mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines,” Journal of Neuroimmunology, vol. 101, no. 1, pp. 1–6, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Tartour, F. Fossiez, I. Joyeux et al., “Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice,” Cancer Research, vol. 59, no. 15, pp. 3698–3704, 1999. View at Google Scholar · View at Scopus
  63. T. Kato, H. Furumoto, T. Ogura et al., “Expression of IL-17 mRNA in ovarian cancer,” Biochemical and Biophysical Research Communications, vol. 282, no. 3, pp. 735–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Huang and C. Lee, “Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-β,” Frontiers in Bioscience, vol. 8, pp. s740–s749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Numasaki, J. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Numasaki, M. T. Lotze, and H. Sasaki, “Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts,” Immunology Letters, vol. 93, no. 1, pp. 39–43, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Saharinen, T. Tammela, M. J. Karkkainen, and K. Alitalo, “Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation,” Trends in Immunology, vol. 25, no. 7, pp. 387–395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Sparmann and D. Bar-Sagi, “Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis,” Cancer Cell, vol. 6, no. 5, pp. 447–458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. I. Kryczek, A. Lange, P. Mottram et al., “CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers,” Cancer Research, vol. 65, no. 2, pp. 465–472, 2005. View at Google Scholar
  71. M. Numasaki, M. Watanabe, T. Suzuki et al., “IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis,” Journal of Immunology, vol. 175, no. 9, pp. 6177–6189, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. R. M. Strieter, M. D. Burdick, B. N. Gomperts, J. A. Belperio, and M. P. Keane, “CXC chemokines in angiogenesis,” Cytokine and Growth Factor Reviews, vol. 16, no. 6, pp. 593–609, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Honorati, S. Neri, L. Cattini, and A. Facchini, “Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts,” Osteoarthritis and Cartilage, vol. 14, no. 4, pp. 345–352, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. S. H. Jeon, B. C. Chae, H. A. Kim et al., “Mechanisms underlying TGF-β1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis,” Journal of Leukocyte Biology, vol. 81, no. 2, pp. 557–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. B. M. M. Zwaans and D. R. Bielenberg, “Potential therapeutic strategies for lymphatic metastasis,” Microvascular Research, vol. 74, no. 2-3, pp. 145–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. J. W. Lee, P. Wang, M. G. Kattah et al., “Differential regulation of chemokines by IL-17 in colonic epithelial cells,” Journal of Immunology, vol. 181, no. 9, pp. 6536–6545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Shojaei, M. Singh, J. D. Thompson, and N. Ferrara, “Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2640–2645, 2008. View at Publisher · View at Google Scholar
  78. D. J. Waugh and C. Wilson, “The interleukin-8 pathway in cancer,” Clinical Cancer Research, vol. 14, no. 21, pp. 6735–6741, 2008. View at Google Scholar
  79. Z. G. Fridlender, J. Sun, S. Kim et al., “Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN,” Cancer Cell, vol. 16, no. 3, pp. 183–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Mantovani, “The yin-yang of tumor-associated neutrophils,” Cancer Cell, vol. 16, no. 3, pp. 173–174, 2009. View at Publisher · View at Google Scholar
  81. L. Wang, N. Salibi, Y. Wu, M. E. Schweitzer, and R. R. Regatte, “Relaxation times of skeletal muscle metabolites at 7T,” Journal of Magnetic Resonance Imaging, vol. 29, no. 6, pp. 1457–1464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. J. P. Zhang, J. Yan, J. Xu et al., “Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 50, no. 5, pp. 980–989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. S. R. Pickens, M. V. Volin, A. M. Mandelin, J. K. 2nd Kolls, R. M. Pope, and S. Shahrara, “IL-17 contributes to angiogenesis in rheumatoid arthritis,” The Journal of Immunology, vol. 184, no. 6, pp. 3233–3241, 2010. View at Publisher · View at Google Scholar
  84. B. Silva-Santos, “Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing γδ T cells,” European Journal of Immunology, vol. 40, no. 7, pp. 1873–1876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Wakita, K. Sumida, Y. Iwakura et al., “Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis,” European Journal of Immunology, vol. 40, no. 7, pp. 1927–1937, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. S. He, M. Fei, Y. Wu et al., “Distribution and clinical significance of TH17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients,” International Journal of Molecular Sciences, vol. 12, no. 11, pp. 7424–7437, 2011. View at Google Scholar
  87. J. Liu, Y. Duan, X. Cheng et al., “IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma,” Biochemical and Biophysical Research Communications, vol. 407, no. 2, pp. 348–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. D. McAllaster and M. S. Cohen, “Role of the lymphatics in cancer metastasis and chemotherapy applications,” Advanced Drug Delivery Reviews, vol. 63, no. 10-11, pp. 867–875, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Candido and T. Hagemann, “Cancer-related inflammation,” Journal of Clinical Immunology, vol. 33, supplement 1, pp. S79–S84, 2013. View at Google Scholar
  90. A. S. Chung, X. Wu, G. Zhuang et al., “An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy,” Nature Medicine, vol. 19, no. 9, pp. 1114–1123, 2013. View at Google Scholar
  91. Z. Su, Y. Sun, H. Zhu et al., “Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis,” Immunologic Research, vol. 58, no. 1, pp. 118–124, 2014. View at Publisher · View at Google Scholar
  92. L. F. Fajardo, H. H. Kwan, J. Kowalski, S. D. Prionas, and A. C. Allison, “Dual role of tumor necrosis factor-alpha in angiogenesis,” The American Journal of Pathology, vol. 140, no. 3, pp. 539–544, 1992. View at Google Scholar
  93. G. L. Beatty and Y. Paterson, “IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ,” Journal of Immunology, vol. 166, no. 4, pp. 2276–2282, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Starnes, M. J. Robertson, G. Sledge et al., “Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production,” The Journal of Immunology, vol. 167, no. 8, pp. 4137–4140, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Castermans, S. P. Tabruyn, R. Zeng et al., “Angiostatic activity of the antitumor cytokine interleukin-21,” Blood, vol. 112, no. 13, pp. 4940–4947, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Kryczek, M. Banerjee, P. Cheng et al., “Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments,” Blood, vol. 114, no. 6, pp. 1141–1149, 2009. View at Google Scholar
  97. Y. Xie, W. Sheng, J. Xiang, Z. Ye, and J. Yang, “Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis,” Cancer Investigation, vol. 28, no. 6, pp. 598–607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. Z. Tong, X. O. Yang, H. Yan et al., “A protective role by interleukin-17F in colon tumorigenesis,” PLoS ONE, vol. 7, no. 4, Article ID e34959, 2012. View at Publisher · View at Google Scholar
  99. T. Shih and C. Lindley, “Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies,” Clinical Therapeutics, vol. 28, no. 11, pp. 1779–1802, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3, pp. 353–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  101. E. Maniati, R. Soper, and T. Hagemann, “Up for Mischief? IL-17/Th17 in the tumour microenvironment,” Oncogene, vol. 29, no. 42, pp. 5653–5662, 2010. View at Publisher · View at Google Scholar
  102. H. A. Alshaker and K. Z. Matalka, “IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors,” Cancer Cell International, vol. 11, article 33, 2011. View at Publisher · View at Google Scholar
  103. P. J. Barnes and M. Karin, “Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases,” The New England Journal of Medicine, vol. 336, no. 15, pp. 1066–1071, 1997. View at Google Scholar
  104. W. Zou and N. P. Restifo, “TH17 cells in tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 10, no. 4, pp. 248–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Martin, L. Apetoh, and F. Ghiringhelli, “Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?” Trends in Molecular Medicine, vol. 18, no. 12, pp. 742–749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. V. Mumprecht and M. Detmar, “Lymphangiogenesis and cancer metastasis,” Journal of cellular and molecular medicine, vol. 13, no. 8, pp. 1405–1416, 2009. View at Google Scholar
  107. D. Massi and Ö. Gököz, “The biological significance of lymphangiogenesis in human tumours,” Diagnostic Histopathology, vol. 16, no. 6, pp. 295–305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Tammela and K. Alitalo, “Lymphangiogenesis: molecular mechanisms and future promise,” Cell, vol. 140, no. 4, pp. 460–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Lohela, M. Bry, T. Tammela, and K. Alitalo, “VEGFs and receptors involved in angiogenesis versus lymphangiogenesis,” Current Opinion in Cell Biology, vol. 21, no. 2, pp. 154–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. X. Chen, J. Wan, J. Liu et al., “Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients,” Lung Cancer, vol. 69, no. 3, pp. 348–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. S. K. Chauhan, Y. Jin, S. Goyal et al., “A novel pro-lymphangiogenic function for Th17/IL-17,” Blood, vol. 118, no. 17, pp. 4630–4634, 2011. View at Publisher · View at Google Scholar
  112. E. Maniati and T. Hagemann, “IL-17 mediates resistance to anti-VEGF therapy,” Nature Medicine, vol. 19, no. 9, pp. 1092–1094, 2013. View at Publisher · View at Google Scholar
  113. M. W. Kieran, R. Kalluri, and Y. Cho, “The VEGF pathway in cancer and disease: responses, resistance, and the path forward,” Cold Spring Harbor perspectives in medicine, vol. 2, no. 12, Article ID a006593, 2012. View at Google Scholar · View at Scopus
  114. P. Muranski, A. Boni, P. A. Antony et al., “Tumor-specific Th17-polarized cells eradicate large established melanoma,” Blood, vol. 112, no. 2, pp. 362–373, 2008. View at Publisher · View at Google Scholar
  115. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Google Scholar
  116. C. H. Xu, P. Zhan, L. K. Yu, and X. W. Zhang, “Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions,” Tumor Biology, vol. 35, no. 2, pp. 1599–1603, 2014. View at Publisher · View at Google Scholar
  117. J. E. Heffner, “Diagnosis and management of malignant pleural effusions,” Respirology, vol. 13, no. 1, pp. 5–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Chomej, K. Bauer, N. Bitterlich et al., “Differential diagnosis of pleural effusions by fuzzy-logic-based analysis of cytokines,” Respiratory Medicine, vol. 98, no. 4, pp. 308–317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. K. B. Sriram, V. Relan, B. E. Clarke et al., “Diagnostic molecular biomarkers for malignant pleural effusions,” Future Oncology, vol. 7, no. 6, pp. 737–752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Klimatsidas, K. Anastasiadis, C. Foroulis et al., “Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions,” Journal of Cardiothoracic Surgery, vol. 7, no. 1, article 104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. Q. Li, Y. Han, G. Fei, Z. Guo, T. Ren, and Z. Liu, “IL-17 promoted metastasis of non-small-cell lung cancer cells,” Immunology Letters, vol. 148, no. 2, pp. 144–150, 2012. View at Publisher · View at Google Scholar
  122. D. Lemancewicz, L. Bolkun, E. Jablonska et al., “The role of interleukin-17A and interleukin-17E in multiple myeloma patients,” Medical Science Monitor, vol. 18, no. 1, pp. BR54–BR59, 2012. View at Google Scholar · View at Scopus
  123. K. M. Dhodapkar, S. Barbuto, P. Matthews et al., “Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma,” Blood, vol. 112, no. 7, pp. 2878–2885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Noonan, L. Marchionni, J. Anderson, D. Pardoll, G. D. Roodman, and I. Borrello, “A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma,” Blood, vol. 116, no. 18, pp. 3554–3563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. A. L. Bannister Khan Jr., A. L. Khan, D. W. Eccleston, R. K. Deol-Poonia, and S. F. Hughes, “Interleukin-17 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence,” ISRN Inflammation, vol. 2012, Article ID 578149, 6 pages, 2012. View at Publisher · View at Google Scholar
  126. D. Chen, Q. Hu, C. Mao et al., “Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer,” Cellular Immunology, vol. 272, no. 2, pp. 166–174, 2012. View at Google Scholar
  127. N. Stanilov, L. Miteva, T. Deliysky, J. Jovchev, and S. Stanilova, “Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels,” Laboratory Medicine, vol. 41, no. 3, pp. 159–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Kirchberger, D. J. Royston, O. Boulard et al., “Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model,” Journal of Experimental Medicine, vol. 210, no. 5, pp. 917–931, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. P. I. Spuls and L. Hooft, “Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal,” British Journal of Dermatology, vol. 167, no. 4, pp. 710–713, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. K. A. Papp, R. G. Langley, B. Sigurgeirsson et al., “Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study,” British Journal of Dermatology, vol. 168, no. 2, pp. 412–421, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. P. Rich, B. Sigurgeirsson, D. Thaci et al., “Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study,” The British Journal of Dermatology, vol. 168, no. 2, pp. 402–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. D. Baeten, X. Baraliakos, J. Braun et al., “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 382, no. 9906, pp. 1705–1713, 2013. View at Google Scholar
  133. I. B. McInnes, J. Sieper, J. Braun et al., “Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial,” Annals of the Rheumatic Diseases, vol. 73, no. 2, pp. 349–356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Reppert, S. Koch, and S. Finotto, “IL-17A is a central regulator of lung tumor growth,” Oncoimmunology, vol. 1, no. 5, pp. 783–785, 2012. View at Google Scholar
  135. S. Reppert, I. Boross, M. Koslowski et al., “A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer,” Nature Communications, vol. 2, no. 1, article 600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. M. F. Neurath and S. Finotto, “The emerging role of T cell cytokines in non-small cell lung cancer,” Cytokine and Growth Factor Reviews, vol. 23, no. 6, pp. 315–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Wu, K. J. Rhee, E. Albesiano et al., “A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses,” Nature Medicine, vol. 15, no. 9, pp. 1016–1022, 2009. View at Publisher · View at Google Scholar
  138. L. Das Roy, L. B. Pathangey, T. L. Tinder, J. L. Schettini, H. E. Gruber, and P. Mukherjee, “Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis,” Breast Cancer Research, vol. 11, no. 4, article R56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Wang, T. S. Yi, M. Kortylewski, D. M. Pardoll, D. F. Zeng, and H. Yu, “IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1457–1464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. Q. Y. Zhang, S. Liu, D. X. Ge et al., “Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models,” Cancer Research, vol. 72, no. 10, pp. 2589–2599, 2012. View at Publisher · View at Google Scholar
  141. W. Chae, T. F. Gibson, D. Zelterman, L. Hao, O. Henegariu, and A. L. M. Bothwell, “Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 12, pp. 5540–5544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. R. A. Droeser, U. Güth, S. Eppenberger-Castori et al., “High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 8, pp. 1295–1302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Cochaud, J. Giustiniani, C. Thomas et al., “IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2,” Scientific Reports, vol. 3, article 3456, 2013. View at Publisher · View at Google Scholar
  144. X. N. Song, J. Z. Yang, L. X. Sun et al., “Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival,” Leukemia Research, vol. 37, no. 9, pp. 1094–1099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  145. Q. Yu, X. M. Lou, and Y. He, “Prediction of local recurrence in cervical cancer by a Cox model comprised of lymph node status, lymph-vascular space invasion, and intratumoral Th17 cell-infiltration,” Medical Oncology, vol. 31, no. 1, article 795, 2014. View at Google Scholar